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Abstract
Systemic sclerosis (SSc) is a progressive vasculopathic, fibrosing autoimmune condition, 
portending significant mortality; wherein interstitial lung disease (ILD) is the leading cause of 
death. Although lacking a definitive cure, therapeutics for (SSc-ILD) that stave progression exist 
with further promising primary and adjuvant compounds in development, as well as interventions 
to reduce symptom burden and increase quality of life. To date, there has been a significant but 
varied history related to systemic sclerosis–related interstitial lung disease trial design and 
endpoint designation. This is especially true of endpoints measuring patient-reported perceptions 
of efficacy and tolerability. This article describes the underpinnings and complexity of the science, 
methodology, and current state of patient-reported outcome measures used in (SSc-ILD) systemic 
sclerosis–related interstitial lung disease in clinical practice and trials.
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Introduction
Systemic sclerosis (SSc) is a complex multi-organ disease of vascular injury, endothelial 
dysfunction, destruction and disrepair with ensuing inflammation, immune activation, and 
dysregulated fibroblastic proliferation with extracellular matrix deposition resulting in 
clinical fibrosis. SSc is highly heterogeneous in degree and type of organ involvement, 
clinical manifestations, severity, rate of progression, and survival. Interstitial lung disease 
(ILD), followed by pulmonary hypertension (PH), is the leading cause of SSc-related death.
1,2
SSc lacks a definitive cure; however, treatment development in SSc, and systemic sclerosis–
related interstitial lung disease (SSc-ILD) especially, is rapidly advancing. Increasing 
numbers of SSc-ILD studies annually yield meaningful information on trial design and 
endpoints for how best to measure therapeutic responsiveness. Beyond traditional markers 
such as computed tomography (CT) scanning and pulmonary function testing (PFTs), 
growing recognition and importance is placed on the group of outcome measures that 
register patients’ perceptions of therapeutic responsiveness and medication tolerability: 
patient-reported outcome measures (PROMs).
PROMs are intended to reflect the positive and negative impact of changes in a health 
condition as experienced by patients in the context of their everyday lives as they try to 
sustain activities of work, social, and family life. This includes treatment side effects and 
disease-related symptoms such as dyspnea, cough, fatigue, and exercise tolerance as well as 
impact on factors such as health-related quality of life (HRQoL), physical function, and 
psychological distress. Patient experience can be described under two overarching and 
overlapping concepts: symptomatology and HRQoL. This article endeavors to impart the 
utility, science, methodologic assurances, challenges, and current state of PROMs in SSc-
ILD for use in clinical trials and practice.
Symptomatology of interest to measure in SSc-ILD
Symptoms of a physical health condition emerge as structural and/or physiological stresses 
are sufficiently extensive to disrupt a patient’s ease of engagement with life activities. The 
behavioral qualities of symptom-related physical impairment are as follows:
1. Presence which can be fleeting and completely resolve—as with pain resulting 
from transient headache or a minor cut when using a kitchen knife; or can be 
constant and/or episodic as with chronic or flaring diseases;
2. Intensity of sensation or impairment which may increase, stabilize, fluctuate, or 
remit;
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3. Trajectory whereby symptoms/impairment may either intensify over time 
perhaps driven by reversible disease activity escalating or irreversible 
progression of damage, remit with disease reversibility through auto-remission or 
treatment, or stabilize with cessation of progression with residual permanent 
damage.
In SSc, inflammation drives acute, reversible disease activity that if not quelled results in 
evolving and then end-stage irreversible fibrosis. Quieting early inflammatory disease may 
reverse symptomatology, while later disease stages with irreversible accrual of damage 
results in more challenging symptom management (Figure 1). In the wake of irreversible 
biophysical damage, improvement of symptom burden may still be possible through non-
disease modifying symptom management strategies.3–12
Based on our prior work, primary lung-related biophysical symptoms of interest to patients 
with SSc and connective tissue disease–related interstitial lung disease (CTD-ILDs) are 
cough, dyspnea, exercise tolerance, and fatigue. In these studies, patients voiced an inability 
to discern whether fatigue was predominantly influenced by underlying ILD or the primary 
CTD itself. Patients communicated these symptom-related impairments via 
contextualization of important life aspects rather than discrete terms such as “breathless.” 
This highlights how the accuracy of symptom-related reporting may be influenced by 
attention to language as well as physical and psychological context.13–17
The multi-organ system involvement of SSc, as well as medication side effects, creates 
diverse and overlapping coincident manifestations and symptoms in a person living with 
SSc. These complicate perceptions of anticipated pulmonary symptoms. For example, 
dyspnea, exercise intolerance, and fatigue in a person with SSc-ILD can arise from effects of 
ILD; but also other experiences common to SSc, such as anemia, cardiopulmonary 
microvascular disease and pulmonary hypertension, infection, myopathy, physical 
deconditioning, multifactorial pain, reflux, systemic inflammation, and common general 
comorbidities such as coronary artery disease, insomnia, obstructive lung disease, and sleep 
apnea.
Symptoms may be imperceptible to the clinician and also unrecognized by the patient 
consistent with the human-drive for adaptability. This adaptability underscores the need for 
careful clinician questioning for patients at risk. Adaptability of pace, intensity, or corporeal 
positioning of activities accommodate for changing physiological circumstance. Patients 
with restrictive lung diseases may, respectively, slow pace or take breaks, add less groceries 
(weight) to shopping bags, change routes to avoid inclines, or forgo optional activities; 
and/or propping chest upright or reducing depth of inspiration to avoid aggravating 
symptoms. Beyond somatic stress, symptoms are multi-layered experiences influenced by 
prognostic uncertainty, cultural overlays and inferences, psychological distress, clinician 
communication, and a patients’ potential for self-efficacy; all of which may contribute to 
patient report.18–20 However, despite the complexity of symptoms in SSc, patient-reported 
“yes/no” on symptom worsening correlates clinically meaningful changes in disease activity 
in SSc patients.21
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Cough has high prevalence in SSc-ILD. Patients report cough being a central ILD 
experience reflecting disease worsening [ref], with adverse impact on HRQoL and disease 
progression in pulmonary fibrosis correlating with radiological extent of fibrosis, decreased 
diffusion capacity, vital capacity, and more dyspnea.14,15,17,22–24 Cough adversely impacts 
HRQoL22–24 whereby physical symptoms like chest pain, sleep disturbance, emesis, and 
incontinence potentially develop25 with complex associations of embarrassment, anxiety, 
depression, and severe disruption of life activities.26 Cough frequency in SSc-ILD decreases 
significantly with immunosuppressive treatment22,23,27 and returns to baseline 1 year after 
withdrawal of treatment.23,27–29 Suggesting that cough may be an independent variable in 
assessing both ongoing fibrosis and therapeutic response in SSc-ILD.23 However, cough 
frequency in SSc-ILD associated with Gastroesophageal reflux disease (GERD) is also 
common and correlates with the presence, severity, and treatment of GERD in SSc-ILD.
HRQoL
Over past decades, growing availability of chemotherapy catalyzed contrasting discussions 
in clinician and patient communities regarding experiences of tolerability/toxicity balanced 
against days of life gained in oncological disease. The medical community’s perspectives on 
survival evolved accounting for HRQoL. “Life at all costs” slowly made way for “informed 
decision-making” whereby patients and families were counseled on side effects and 
projected length of post-treatment survival; more recently, “goal-oriented care” incorporates 
patients’ priorities of daily living in treatment decisions. This conceptual trajectory 
increasingly illuminated survival, from regulatory and practice standpoints, as an important 
but not an exclusive indication of successful treatment. Recently, as an example, qualitative 
studies in idiopathic pulmonary fibrosis (IPF), a fatal progressive disease, highlighted patient 
concerns that disease-slowing medication side effects may severely limit meaningful life 
interactions and need to be balanced as a trade off against survival.8,30,31
Broad concepts of preventing/reducing disability and augmenting function in the context of 
survival32,33 under-pin the utility of PROMs. Traditional disease measures characterize 
fluctuations of biophysiological processes; from which clinicians can only imagine how 
poorly or well a patient is able to live their lives. HRQoL PROMs, if well-developed, 
provide scientific quantification of the impact of a health condition, reliably capturing health 
condition-related changes in “the stuff that life is made of” including symptoms, function, 
mental health, energy, workability, and coping, in other words the quality of one’s life lived. 
HRQoL PROMs may have discrete components for physical function, energy/fatigue, 
psychological distress (anxiety, depression), as well as biophysical symptomatology.
Physical function relates directly to physical limitations resulting from a health condition. It 
is often captured in HRQoL but can be a discrete measure, such as the Health Assessment 
Question-Disability Index (HAQ-DI), used in addition to a generic (see below) global 
HRQoL measure. The HAQ-DI is the basis for the SHAQ (Scleroderma Health Assessment 
Questionnaire)34,35 that includes six visual analogue scale (VAS) items assessing the 
perceived severity of pain, Raynaud’s phenomenon, digital ulcers, breathing, 
gastrointestinal, and overall health related to SSc.
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Importantly for clinical trials, interventions may improve HRQoL and physical function but 
not coincide with changes in disease activity. This can occur with palliating medication side 
effects, treating depression/anxiety, improved access to care or clinician communication, 
providing education or assistive or mobility devices, and work accommodations.3,4,11,12,32
Outcome measures
We expect outcome measures to correlate with disease activity and trajectory. Clinical trial 
design in SSc-ILD accommodate for therapies that perform at different levels of efficacy: to 
improve lung function,28,29,36–39 or prevent or delay worsening of progressive functional 
loss.40 This helps differentiate between potential powerful first-line and adjuvant supportive 
therapies in this enigmatic disease.
In regard to terminology, “PROM” is the scientifically appropriate abbreviation. If “PRO” is 
used, a qualifying noun, such as “measure,” “instrument,” “questionnaire,” and “endpoint” 
is required.41
Historical perceptions of objectivity
Over the centuries, Western medical science preferred credence in traditional “objective” 
measures. However, upon reflection, few measures are truly objective, that is, resulted 
without fallible inference. For instance, physical examination components or clinical 
investigations, such as imaging, remain largely unquestioned as “objective” but in fact these 
rely upon human observation, examination and, then, interpretation; each phase inherently 
subjectively influenced by psychological, educational, environmental, and belief tendencies. 
Despite this, the label “objective,” suggestive of higher scientific quality and value, 
continues to apply to clinician-interpreted outcome measures. However, given adequate 
opportunity, patient-reported history provides the greatest proportion of diagnostic 
information, honed then by physical examination findings, with diagnostic testing for 
confirmation.42 Henceforth, we refrain from using “objective” or “subjective” rather 
referring to measures as “diagnostic” or “traditional” and “patient-reported.”
Outcome measure qualities
Whether an instrument be patient-reported or traditional, in order to demonstrate its value as 
a measure, performance testing under multiple criteria increases the quality of an outcome 
measure. The more validation strategies and observations an instrument undergoes leads to 
increasing confidence in that measure. Albeit, there are many instruments that are under-
validated in use both in practice and research, but fulfill a yet unmet need by a more 
substantial measure. One such example is forced vital capacity (FVC). Despite being a 
flawed measure vulnerable to influences by comorbidities, administration and equipment 
variance, and dependence on factors influencing patient performance, it currently is the best 
traditional measure to mark the trajectory of restrictive lung disease.15
The validity of a measure is determined by its content (relevance, comprehensiveness, purity 
of intent; for example, red = actual red, all shades of red, all things that are red), construct 
(conceptually sound in performance, for example, red = red if red exists, not yellow = red), 
and criterion-related (correlates with an external instrument measuring the same construct, 
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for example, identifies between red and not-red in accord with external instrument). “Unified 
construct validity” theory accounts for each of these validity concepts as different facets of a 
single validation effort.
Beyond validation strategies, essential performance observations establish a measure’s 
confidence in utility. These important benchmarks to demonstrate are as follows:
• Reliability, regardless of scale the measure will perform consistently every time 
(even if measuring the wrong construct, it will do so every time).
• Discrimination, ability to distinguish from a similar but not accurate other 
construct.
• Responsiveness, ability to register change in the construct over time with disease 
worsening or improvement. Not necessary for tools with a single time-point 
assessments such as for screening, staging, or diagnosis.
• Practicability, speaks to issues of ease of use, access, and safety:
– Interpretability, the degree to which instrument’s results are easily 
interpreted.
– Access, the extent to which the instrument is commonly available.
– Cost, financial practicalities of implementation.
– Time-intensiveness, sometimes related to cost of administration, 
interpretation; but also the burden of time on patients. Sometimes 
related to fatigue for technician or patient in active performance.
– Safety, the degree of risk for technician or patient.
These concepts are foundational in discerning what constitutes an ideal measure, and what 
could improve an adequate measure. Furthermore, PROMs may have an established minimal 
clinically important difference (MCID) in clinical use; however, study results may 
demonstrate statistically significant change that does not correlate to MCID benchmark of 
that PROM and vice versa.43–45 Often, this disparity is not considered as poor PROM 
performance but rather reported factually in the study results leaving readers or regulatory 
agencies to interpret.
A PROM may be either generic (used across health conditions) or may be disease- or 
symptom-specific. An example of such is the Short Form-36 for generic HRQoL and St 
George’s Respiratory Questionnaire as respiratory-specific HRQoL. There are benefits to 
each type; generic measures are often performance validated across many diseases, and 
generic measures also confer generalizability for disease comparisons. Generic measures can 
act as benchmark measures for construct validity of under-validated measures. Although 
anticipated to correlate with generic PROMs, disease-specific PROMS provide distinctive 
disease-related information hopefully conferring greater reliability, discrimination and 
sensitivity to change.
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Path to PROM development
Food and Drug Administration (FDA) and European Medicines Agency (EMA) mandate 
that patient-reported data collection and PROM development be implemented with sound 
scientific methodology essentially informed by the experience and priorities directly from 
patients through qualitative research.41,46 Qualitative research for scientific and health 
intervention purposes, whether for trial end-points, educational tools, or other purposes, 
represents the patient’s voice; ensuring accuracy relies on exacting and exhaustive methods, 
with careful attention to context and language.
Although not a precise reproducible science, qualitative research is qualified by standards 
reflecting validity (credibility), objectivity (confirmability), and generalizability 
(transferability). FDA/EMA patient-centered regulations established new demands on 
therapeutic research. However, distinguishing quick, dilute methods sufficient for marketing 
research purposes from stringent methodology driving scientific research for patient well-
being and therapeutic advancement is essential. The most accepted quality assessment for 
journal publication, the COREQ (consolidated criteria for reporting qualitative research),
47,48 is a 32-item checklist ensuring the rigor of the qualitative research. The COREQ 
examines qualitative rigor with several questions under each of three domains: study team, 
study design, and analysis and findings.
We present seven overarching steps required to occur in robust PROM development (Table 
1):
• Team. Convening a qualified team which should include patient research 
partners, clinician expertise, qualitative researchers, and psychometricians.
• Question. Clarifying the need and goals of PROM research, for example, 
screening versus monitoring, generic versus disease/symptom specific, and 
physical versus inclusion of psychosocial aspects, which may include literature 
review and preliminary qualitative investigations.
• Design. Designing the research to ensure saturation of relevant concepts resulting 
in a conceptual framework that supports a wide and accurate item collection 
while assuring the required level of diversity within the disease of interest.
• Implementation and qualitative analysis. Focus groups with interval iterative 
analyses for assessment of concept saturation, framework revision, and 
distillation of discrete concepts.
• Field-testing. Field-testing of concepts and initial questionnaire items, including 
field-testing items for relevance of concept, language, phrasing, and preferred 
response format, can be accomplished with qualitative investigations or in 
combination with quantitative surveying for larger response.
• Item reduction and fit. Quantitative field-testing may support item reduction but 
psychometric testing is essential using one or more approaches from Rasch 
analysis, factor analysis, and/or item response theory to reduce items and test 
item fit.49–51
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• Validation. Validation is a multi-step process, initial testing with test–retest 
validation, with unified validation taking place in the context generally of 
registries or as an exploratory endpoint in clinical trials.
Developmental deviations
Deviations from FDA/EMA PROM guidance exist, the most common being utilization of 
older, pre-guidance, performance-validated PROMs developed without patient-centered 
qualitative inquiry but rather via clinician conjecture and observation, e.g. HAQ-DI, 
SF-36.52 Borrowed PROMs developed for other diseases like chronic obstructive pulmonary 
disease (COPD), for example, SGRQ (St. George’s Respiratory Questionnaire), Borg, or 
MTDI (Mahler Transitional Dyspnea Index), when used in SSc-ILD, can provide a needed 
measure when a disease-specific measure is lacking.28,29,40 Adapted PROMs, using 
qualitative field-testing to amend PROMs to fit a new disease, such as ILD versions of 
SGRQ and Dyspnea-12 or to establish compliance with FDA/EMA guidance,53,54 eliminates 
foundational steps and may not be sufficient to capture patient priorities and relevance to the 
particular disease experience. While PROMs with abbreviated development have utility in 
filling a care and research gap, optimal endpoint performance with robust methodology for 
patient content16,55 remain an important concern especially for diseases like SSc-ILD that 
present assessment challenges.
PROMs of interest in SSc-ILD
Measuring patient-reported changes in SSc-ILD and other CTD-ILDs where there may be 
multiple organ involvement and where the further burden of medication side effects is 
complex. This section describes symptom and HRQoL PROMS used in SSc-ILD trials 
(Tables 2–4).
Dyspnea.
Respiratory-specific HRQoL instruments, such as the SGRQ, reflect the burden of 
respiratory symptoms, whereas dyspnea-specific instruments have demonstrated utility in 
assessing symptom response to treatment.65,66
SHAQ Breathing VAS is the simplest, most direct, and robustly validated dyspnea measure 
in SSc-ILD. It is a single-item scale and correlates with FVC, high-resolution computed 
tomography (HRCT), and HRQoL measures.28,29 The Borg scale, another single-item 10-
point scale validated across several pulmonary conditions,67,68 assesses pre/post exercise 
dyspnea, for example, 6-min walk test (6MWT).69 In SSc-ILD, rest/post-6MWT Borg 
scores demonstrated reproducibility and correlated to distance.70,71
The Medical Research Council Breathless Scale (MRC) queries dyspnea on five scaled 
statements of dyspnea in relation to life activities, akin to the NYHA Classification, has 
strong utility in stratifying severity but with threshold limits in serial change. The MRC, 
validated in IPF but not SSc-ILD,72 demonstrated responsiveness, reproducibility, and 
construct validity73,74 and independently predicted anxiety and depression in ILD.75
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Mahler indexes, developed for COPD,76 consist of three abstract questions staff-
administered examining changes in “functional impairment,” “magnitude of task,” and 
“magnitude of effort.” The implementation and results are administrator-dependent, but they 
demonstrated partial validation with ability to predict treatment responsiveness in SSc-ILD 
and distinguish between treatment-related improved FVC versus placebo-related worsening.
28,77
The UCSD-SOBQ, a quick 24-item instrument with short question stems of 1–3 words and a 
6-point response scale, has demonstrated validity in ILDs including SSc-ILD78,79 and IPF.65 
Its psychometric soundness presumes the ease of comprehension and the contextualization 
demonstrated to be important in patient communication of dyspnea14–17; however, it is 
unknown if contextualization of physical activities in the UCSD-SOBQ is confounded by 
systemic and musculoskeletal symptoms. Contextualization, though useful, can be highly 
personal. The UCSD-SOBQ has only two items querying psychological aspects with both 
relating to fear.
The Dyspnea-12, 12 simple statements of which six focus on the breathing act and six on 
affective aspects of breathing using a 4-point scale, demonstrated reliability in ILDs 
including SSc-ILD53,74,80 and correlates with 6MWD.74 Dyspnea-12 targets breath 
perception and avoids contextualizing activities which may be a strategy to help the 
respondent separate breathing from systemic symptoms, for this reason D-12 was accepted 
as a potential measure for future studies.15
The Functional Assessment of Chronic Illness Therapy–Dyspnea (FACIT-D), a 10-item 
activity-based questionnaire very similar to the HAQ-DI with responses focused on 
breathing in relation to daily self-care, therefore contextualizing with essential daily 
activities was validated in an SSc-ILD cohort.81
Cough.
Several instruments measure cough severity, frequency, intensity, and/or impact on HRQoL.
82 The Leicester Cough Questionnaire (LCQ), though not developed for restrictive lung 
disease, has been the most commonly used cough instrument in SSc-ILD and other ILDs as 
both a measure of symptom severity and cough-related HRQoL.15,29,83 The Cough Quality-
of-Life Questionnaire (CQLQ)83,84 is a cough-specific symptom and HRQoL instrument 
with good internal reliability and total score responsiveness in IPF, but performed less 
sensitively to extreme physical and psychological symptoms26,85–87 with ceiling effect 
possibly related to a static 4-point response scale.
The modified cough index (MCI)28,29,85–89 assessed frequency, severity, and phlegm 
production on a 3-point scale, despite SSc-ILD’s association with predominantly dry, 
inspiratory cough, MCI demonstrated responsiveness. VAS are a simpler serial assessment 
of cough severity and or frequency, and easy to include as study construct measure. Neither 
the LCQ nor CQLQ contain direct questioning on cough severity or frequency as do the 
VASs.
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In SSc-ILD, beyond being a composite of disease-related impact, HRQoL often reflects 
trade-offs between treatment efficacy and side effects that also introduce physical or mental 
fatigue, gastrointestinal symptoms, or recurrent infection. The SF-36,52 Patient Global 
Assessment (PtGA), SHAQ,35 and SGRQ54,90 are used most extensively across ILD studies.
The SF-36, a generic measure, can be sub-divided into independently scored domains 
addressing mental health, physical health and function, fatigue, and pain, allowing for 
following these domains and also analyzing the largest contributor to the total SF-36 score. 
In the SLS I trial, MTDI and VAS Breathing correlated highly with each other; however, 
SF-36 was able to differentiate patients with worse dyspnea, FVC, and diffusion capacity of 
the lung for carbon monoxide (DLCO),27 emphasizing the utility of SF-36 in SSc-ILD. 
PtGA VAS is a generic HRQoL measure whose wording can be altered to specify a health 
condition, is validated across rheumatic and non-rheumatic diseases, correlates with 
dyspnea, and recommended for use in CTD-ILD trials.15,35,80
The HAQ-DI is widely validated across many health conditions and addresses a component 
of HRQoL, physical function, which is anticipated to improve with treatment efficacy. The 
SHAQ is the HAQ-DI with five VAS items specific to scleroderma manifestations 
(Raynaud’s phenomenon, digital ulcers, gastrointestinal, breathing, pain), the sixth VAS 
being a PtGA.
At present, no concise ILD or SSc-ILD-specific HRQoL PROM assesses the experiential 
benefits or detriments of treatments. This lack has led to uncertainty and difficulties in 
confidently interpreting PROM results.40 The SGRQ demonstrated acceptable validity and 
reliability in ILD, responsive in CTD-ILD31,91,92 and may be an independent predictor of 
disease progression in ILD.31
Fatigue.
Fatigue, a multi-dimensional phenomenon, struggles to be understood in the context of 
disease both phenomenologically as a living experience and also as discrete measurable 
components for clinical trials and practice.93 Rheumatoid arthritis was the first autoimmune 
disease establishing patient-reported fatigue as a reliable, reproducible outcome that is 
sensitive to change over time.94 Multi-factorial etiology may contribute to distinct fatigue 
types (mental/cognitive, motivational, physical, etc.); in autoimmune diseases, overlapping 
etiologies complicate CTDs with CTD-ILD patients reporting inability to distinguish 
between CTD versus ILD fatigue.15,17 Beyond the mental and physical dysregulation that 
inflammatory milieu confer on hypothalamus, brain, muscle, bone and constitution, resultant 
pain, sedentary susceptibility, and logistical burden confer yet other discrete fatigue sources. 
The presence of ILD confers yet different potential sources of fatigue related to the systemic 
sub-acute impact of lung impairment on muscle, brain, and other tissues.93 Despite this 
complexity, fatigue remains an indiscriminant phenomenon reported as a general measure 
sometimes under the reverse phenomenon of energy or vitality. To date, it is unknown which 
fatigue scale is optimal in SSc-ILD; the FACIT-Fatigue and the SF-36s Vitality profile have 
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both demonstrated feasibility and correlate with changes in FVC; however, this may be true 
of simpler scales such as fatigue/energy VAS.
Coping/self-efficacy.
A number of scales95–97 have been developed to control for improvement in patient 
management and coping of disease that may impact other patient-reported variables such as 
HRQoL, physical function, and fatigue despite lack of improvement in underlying biological 
disease processes. For clinical practice, we discuss this concept further under “Future 
directions.”
Future directions
Improved dyspnea and cough measures
None of the above instruments were developed specifically for ILD or developed by current 
accepted methodology; while current instruments may suffice, an argument can be made for 
more reliable and sensitive patient-reported data collection. Preliminary guidelines for future 
CTD-ILD studies supported development of new questionnaires.15 Although highly 
individualized, contextualization is an important aspect of dyspnea communication. Many 
examples persist, within the question concept of lawn-mowing: some patients may have no 
lawn, and some patients simply stop mowing making that contextualization defunct. 
Whereas some personal and high-priority contexts are not captured in current PROMs, for 
example, “reading a bedtime story at night” or “giving the children a bath.”14,17 Novel 
PROMs where patients set their own context for priority items warrant investigation. 
Furthermore, simple response anchors reflecting “decline-no change-improvement” may 
better capture serial change and lessen recall bias.21,98
Patients perceive that cough is central to ILD behavior and supported by traditional 
measures. The cough in ILD is a different experience than that of COPD;13,14,17,22 
furthermore, SSc-ILD cough requires discrimination between other entities such as reflux. 
Although the LCQ demonstrated sufficient performance in SSc-ILD, measures from the 
patient-centered disease experience may enhance accuracy therapeutic trials and clinical 
practice.
Screening tools for ILD
Given that the largest volume of lung is lost in the first 2 years of SSc-ILD,99 confident 
screening mechanisms are essential for early detection and appropriate treatment of this high 
risk, deadly manifestation. Beyond traditional screening procedures, a careful inquiry 
approach can reveal changes in patterns of breathing, exercise tolerance, and inspiratory dry 
cough. Current respiratory system PROMs are not developed for early detection but rather 
monitoring an existing recognised symptom. An SSc-ILD screening tool comprised content, 
language, and contextual characteristics bearing sufficient sensitivity to disclose adaptation 
to symptoms, but specificity to discern between ILD and other causes of similar symptoms 
could provide great utility in clinical practice.
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Concurrent response data collection
An interesting question is the tandem data collection on sentinel extra-pulmonary 
manifestations in multi-organ diseases such as SSc-ILD as a service to treatment 
advancement in SSc. For example, digital ulcer, musculo-skeletal, or gastrointestinal 
response to treatment intended for SSc-ILD. There are no guidelines or recommendations 
for such, but there is potential value of an SSc-ILD trial to provide significant insight into 
other systemic manifestations in this enigmatic disease and future trials should consider this 
design augmentation.
Patient-reported experience measures (PREMs)
Patient-reported experience measures (PREMs) complement PROMs and are used to gather 
information from patients on their experiences of health services and/or systems in order to 
improve those services for a specified health condition. A PREM in rheumatoid arthritis 
already exists and a PREM for IPF is in development. PREMs create roadmaps that guide 
development of clinical services and test innovations in eight validated domains: Respect for 
patient-centered values, preferences, and expressed needs; Co-ordination and integration of 
care; Information, communication, and education; Physical comfort; Emotio nal support; 
Involvement of family and friends; Transition and continuity; and Access to care.100 Applied 
results build on detected system strengths while addressing weaknesses with innovations 
often developed with qualitative methods, and changes then retested with the PREM.
Patient activation measures (PAMs)
Patient activation measures (PAMs) assess patient engagement and knowledge of their health 
condition. The PAM originated as a 22-item measure and subsequently modified to a short 
form 13-item instrument,101,102 although there are several other similar well-validated 
instruments.95–97,103 Although it can be used for group-based research or clinical trials to 
control for the influence of increasing self-efficacy, the primary use of PAMs is to detect and 
address areas of patient self-management strengths and weaknesses with the goal of 
improved health outcomes. PAMs in ILD are currently being examined by the authors.
Conclusion
PROMs are an essential reflection of a patient’s experience of disease for clinical practice 
and clinical trials. Accurate assessment of patient experiences of SSc-ILD is complicated by 
overlapping manifestations creating similar symptoms, treatment side effects, and disease-
related psychosocial burden. The value of treatment is balanced between survival and long-
term tolerability. Development of PROMs and other patient-centered material require care 
and rigor to accurately reflect patient voice and priorities, all undertakings should be 
reported with scientific quality benchmarks. Future work is warranted in PROM 
development for ILD screening, disease activity, symptomatology, healthcare service 
experience as well as patient engagement.
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Table 1.
Proposed overarching concepts of PROM planning and development.
Team
Convening a qualified team
Question
Clarifying the need and goals of PROM research
Design
Designing the research to ensure saturation of concepts in relevant population
Implementation and qualitative analysis
Data collection, iterative analyses and revision leading to concept saturation and conceptual framework
Field-testing
Testing items for relevance of concept, language, phrasing and response format
Item reduction and fit
Quantitative field-testing for item reduction and psychometric testing
Validation
Multi-step process examining performance
PROM: patient-reported outcome measures.
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